

## SUMMARY OF PRODUCT CHARACTERISTICS

### 1. NAME OF THE MEDICINAL PRODUCT

RENOCIS 1 mg kit for radiopharmaceutical preparation

### 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each vial contains 1 mg of succimer (dimercaptosuccinic acid - DMSA).

The radionuclide is not part of the kit.

For the full list of excipients, see section 6.1.

### 3. PHARMACEUTICAL FORM

Kit for radiopharmaceutical preparation.  
White lyophilizate

### 4. CLINICAL PARTICULARS

#### 4.1. Therapeutic indications

This medicinal product is for diagnostic use only.

After radiolabelling with sodium pertechnetate ( $^{99m}\text{Tc}$ ), the solution of technetium ( $^{99m}\text{Tc}$ ) succimer obtained is indicated for:

- the study of the renal cortex morphology
- the study of individual kidney function.
- the location of ectopic kidney.

#### 4.2. Posology and method of administration

##### Posology

##### *Adults and elderly population*

The recommended activity is 30 to 120 MBq for a patient of 70 kg bodyweight.

##### Renal impairment

Careful consideration of the activity to be administered is required since an increased radiation exposure is possible in these patients.

##### *Paediatric population*

The use in paediatric children and adolescents has to be considered carefully, based upon clinical needs and assessing the risk/benefit ratio in this patient group. The activities to be administered to children and to adolescents may be calculated according to the recommendations of the European Association of Nuclear Medicine (EANM 2016) paediatric dosage card, by multiplying a baseline activity (for calculation purposes) by the weight-dependent multiples given in the table below:

$A[\text{MBq}]_{\text{Administered}} = \text{Baseline Activity} \times \text{Multiple}$  (with a baseline activity of 6.8)

Body Mass	Multiple	Body Mass	Multiple	Body Mass	Multiple
3 kg	<b>1*</b>	22 kg	<b>5.29</b>	42 kg	<b>9.14</b>
4 kg	<b>1.14*</b>	24 kg	<b>5.71</b>	44 kg	<b>9.57</b>
6 kg	<b>1.71*</b>	26 kg	<b>6.14</b>	46 kg	<b>10.00</b>
8 kg	<b>2.14*</b>	28 kg	<b>6.43</b>	48 kg	<b>10.29</b>
10 kg	<b>2.71*</b>	30 kg	<b>6.86</b>	50 kg	<b>10.71</b>
12 kg	<b>3.14</b>	32 kg	<b>7.29</b>	52-54 kg	<b>11.29</b>
14 kg	<b>3.57</b>	34 kg	<b>7.72</b>	56-58 kg	<b>12.00</b>
16 kg	<b>4.00</b>	36 kg	<b>8.00</b>	60-62 kg	<b>12.71</b>
18 kg	<b>4.43</b>	38 kg	<b>8.43</b>	64-66 kg	<b>13.43</b>
20 kg	<b>4.86</b>	40 kg	<b>8.86</b>	68 kg	<b>14.00</b>

\*) If the result of the calculation is less than 18.5 MBq, the recommended minimum activity of 18.5 MBq should be used in order to obtain images of sufficient quality.

### **Method of administration**

For intravenous use.

For multidose use.

### *Precautions to be taken before handling or administration of the medicinal product*

This medicinal product should be radiolabelled before administration to the patient.

For instructions on radiolabelling and control of the radiochemical purity of the medicinal product before administration, see section 12.

For patient preparation, see section 4.4.

### **Image acquisition**

The images can be obtained by static (planar or tomographic) acquisitions between 1 to 3 hours post-injection. Where there is renal impairment or obstruction, delayed views may be needed (6 to 24 hours respectively).

### **4.3. Contraindications**

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. or to any of the components of the labelled radiopharmaceutical.

### **4.4. Special warnings and precautions for use**

#### **Potential for hypersensitivity or anaphylactic reactions**

If hypersensitivity or anaphylactic reactions occur, the administration of the medicinal product must be discontinued immediately and intravenous treatment initiated, if necessary. To enable immediate action in emergencies, the necessary medicinal products and equipment such as endotracheal tube and ventilator must be immediately available.

#### **Individual benefit/risk justification**

For each patient, the radiation exposure must be justifiable by the likely benefit. The activity administered should in every case be as low as reasonably achievable to obtain the required diagnostic information.

### Renal impairment

Careful consideration of the benefit risk ratio in these patients is required since an increased radiation exposure is possible (see section 4.2).

### Paediatric population

For information on the use in paediatric population, see section 4.2.

Careful consideration of the indication is required since the effective dose per MBq is higher than in adults (see section 11).

### Patient preparation

The patient should be well hydrated before the start of the examination and urged to void as often as possible during the first hours after the examination in order to reduce radiation.

### Specific warnings

This medicinal product contains less than 1 mmol of sodium (23 mg) per vial, i.e. is essentially 'sodium-free'.

Precautions with respect to environmental hazard are in section 6.6.

## **4.5. Interaction with other medicinal products and other forms of interaction**

Some chemical compounds or medicaments may affect the function of tested organs and influence the uptake of technetium ( $^{99m}\text{Tc}$ ) succimer:

- Ammonium chloride: may substantially reduce renal uptake and increase hepatic uptake of technetium ( $^{99m}\text{Tc}$ ) succimer.
- Sodium bicarbonate: reduction of renal uptake of technetium ( $^{99m}\text{Tc}$ ) succimer.
- Mannitol: reduction of renal uptake of technetium ( $^{99m}\text{Tc}$ ) succimer.
- ACE inhibitors (e.g. captopril) may cause reversible failure of tubule function as a result of the reduction in filtration pressure in a kidney that is affected by renal artery stenosis. This in turn leads to reduced renal concentration of technetium ( $^{99m}\text{Tc}$ ) succimer.  
To avoid these influences, treatment with any of the above chemical products should be interrupted where possible.
- Chemotherapy: Experimental research in animals has demonstrated that methotrexate, cyclophosphamide or vincristine can affect the biodistribution of technetium ( $^{99m}\text{Tc}$ ) succimer.

## **4.6. Fertility, pregnancy and lactation**

### ***Women of childbearing potential***

When an administration of radiopharmaceuticals to a woman of childbearing potential is intended, it is important to determine whether or not she is pregnant. Any woman who has missed a period should be assumed to be pregnant until proven otherwise. If in doubt about her potential pregnancy (if the woman has missed a period, if the period is very irregular, etc.), alternative techniques not using ionising radiation (if there are any) should be offered to the patient.

### ***Pregnancy***

Radionuclide procedures carried out on pregnant women also involve radiation doses to the foetus. Only essential investigations should be carried out during pregnancy, when the likely benefit exceeds the risk incurred by mother and foetus.

## Breastfeeding

Before administering radiopharmaceuticals to a mother who is breast-feeding consideration should be given to the possibility of delaying the administration of radionuclide until the mother has ceased breast-feeding, and to what is the most appropriate choice of radiopharmaceuticals, bearing in mind the secretion of activity in breast milk. If the administration is considered necessary, breast-feeding should be interrupted for 4 hours and the expressed feeds discarded.

## Fertility

No study on fertility has been performed.

### 4.7. Effects on ability to drive and use machines

Renocis has no or negligible influence on the ability to drive and use machines.

### 4.8. Undesirable effects

The adverse events are presented in the table below by the MedDRA System Organ Class and with a not known frequency (cannot be estimated from the available data):

MedDRA Body system SOCs	Preferred term	Frequency
Immune system disorders	Hypersensitivity	Not known

Allergic reactions have been reported in the literature.

Exposure to ionising radiation is linked with cancer induction and a potential for development of hereditary defects.

As the effective dose is 1.06 mSv when the maximal recommended activity of 120 MBq is administered these adverse effects are expected to occur with a low probability.

#### Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system.

#### **Finland**

www-sivusto: [www.fimea.fi](http://www.fimea.fi)

Lääkealan turvallisuus- ja kehittämiskeskus Fimea

Lääkkeiden haittavaikutusrekisteri

PL 55

00034 FIMEA

### 4.9. Overdose

In the event of the administration of a radiation overdose with technetium ( $^{99m}\text{Tc}$ ) succimer the absorbed dose to the patient should be reduced where possible by increasing the elimination of the radionuclide from the body by forced diuresis and frequent bladder voiding. It might be helpful to estimate the effective dose that was applied.

## 5. PHARMACOLOGICAL PROPERTIES

### 5.1. Pharmacodynamic properties

Pharmacotherapeutic group: Diagnostic radiopharmaceuticals for the renal system, Technetium ( $^{99m}\text{Tc}$ ) compounds  
ATC code: V 09 CA 02.

#### **Pharmacodynamic effects**

At the chemical concentrations used for diagnostic procedures technetium ( $^{99m}\text{Tc}$ ) succimer does not appear to exert any pharmacodynamic effects.

### 5.2. Pharmacokinetic properties

#### **Distribution**

Technetium ( $^{99m}\text{Tc}$ ) succimer is cleared from blood with a triphasic pattern in patients with normal renal function.

#### **Organ uptake**

The technetium ( $^{99m}\text{Tc}$ ) succimer localizes in high concentrations in renal cortex. Maximal localization occurs within 3-6 hours after intravenous injection, with about 40-50 % of the dose retained in the kidneys. Less than 3 % of the administered dose localizes in the liver. However, this amount can be increased significantly and renal distribution decreased in patients with impaired renal functions.

#### **Elimination**

Excretion is exclusively via the kidneys.

#### **Half-life**

The effective half-life of technetium ( $^{99m}\text{Tc}$ ) succimer in blood is around 1 hour.

### 5.3. Preclinical safety data

Toxicity with repeated administration of 0.66 mg/kg/day succimer and 0.23 mg/kg/day  $\text{SnCl}_2$  over 14 days in rats was not observed. The dose usually administered to humans is 0.14 mg/kg succimer.

This agent is not intended for regular or continuous administration.

Mutagenicity studies and long-term carcinogenicity studies have not been carried out.

## 6. PHARMACEUTICAL PARTICULARS

### 6.1 List of excipients

Stannous chloride dihydrate (E 512)  
Inositol  
Ascorbic acid (E 300)  
Sodium hydroxide (E 524) (for pH adjustment)  
Under nitrogen atmosphere (E 941)

## 6.2. Incompatibilities

This medicinal product must not be mixed with other medicinal products except those mentioned in section 12.

## 6.3. Shelf life

1 year.

The expiry date is indicated on the outer packaging and on each vial.

After radiolabelling: do not store above 25°C and use within 8 hours.

## 6.4. Special precautions for storage

Store the kit in a refrigerator (2°C – 8°C)

For storage conditions after radiolabelling of the medicinal product, see section 6.3.

Storage of radiopharmaceuticals should be in accordance with national regulation on radioactive materials.

## 6.5. Nature and contents of container

Colourless, type I 15-ml glass vials closed with bromobutyl stopper and polypropylene lid welded to an aluminium crimp capsule.

Pack size: 5 multidose vials.

## 6.6. Special precautions for disposal and other handling

### General warnings

Radiopharmaceuticals should be received, used and administered only by authorised persons in designated clinical settings. Their receipt, storage, use, transfer and disposal are subject to the regulations and/or appropriate licences of the competent official organisation.

Radiopharmaceuticals should be prepared in a manner which satisfies both radiation safety and pharmaceutical quality requirements. Appropriate aseptic precautions should be taken.

Content of the vial is intended only for use in the preparation of technetium ( $^{99m}\text{Tc}$ ) succimer and is not to be administered directly to the patient without undergoing the preparative procedure.

For instructions on extemporaneous preparation of the medicinal product before administration, see section 12.

If at any time in the preparation of this product the integrity of this vial is compromised it should not be used.

Administration procedures should be carried out in a way to minimise risk of contamination of the medicinal product and irradiation of the operators. Adequate shielding is mandatory.

The content of the kit before extemporaneous preparation is not radioactive. However, after sodium pertechnetate ( $^{99m}\text{Tc}$ ) injection is added, adequate shielding of the final preparation must be maintained.

The administration of radiopharmaceuticals creates risks for other persons from external radiation or contamination from spills of urine, vomiting, or any other biological fluids. Radiation protection precautions in accordance with national regulations must therefore be taken.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

## **7. MARKETING AUTHORISATION HOLDER**

CIS bio international  
B.P.32  
F-91192 Gif sur -Yvette Cedex

## **8. MARKETING AUTHORISATION NUMBER**

Finland: 11247

## **9. DATE OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION**

### **Date of first authorisation:**

Finland: 29/11/1993

### **Date of last renewal:**

Finland: 18/08/2009

## **10. DATE OF REVISION OF THE TEXT**

07/2025

## **11. DOSIMETRY**

Technetium ( $^{99m}\text{Tc}$ ) is produced by means of a  $^{99}\text{Mo}/^{99m}\text{Tc}$  generator and decays with the emission of gamma radiation with a mean energy of 140 keV and a half-life of 6.02 hours to technetium ( $^{99}\text{Tc}$ ) which, in view of its long half-life of  $2.13 \times 10^5$  years can be regarded as quasi stable.

The data listed below are from ICRP 128.

<sup>99m</sup> Tc-DMSA	Absorbed dose per unit activity administered (mGy/MBq)				
Organ	Adult	15 years	10 years	5 years	1 year
Adrenals	0.012	0.016	0.024	0.035	0.060
Bone surfaces	0.005	0.0062	0.0092	0.014	0.026
Brain	0.0012	0.0015	0.0025	0.0040	0.0072
Breast	0.0013	0.0018	0.0028	0.0045	0.0084
Gallbladder wall	0.0083	0.010	0.014	0.022	0.031
Gastrointestinal tract					
Stomach wall	0.0052	0.0063	0.010	0.014	0.020
Small intestine wall	0.0050	0.0064	0.010	0.014	0.024
Colon wall	0.0043	0.0055	0.0082	0.012	0.020
(Upper large intestine wall	0.0050	0.0064	0.0095	0.014	0.023
Lower large intestine wall)	0.0033	0.0043	0.0065	0.0096	0.016
Heart wall	0.0030	0.0038	0.0058	0.0086	0.014
Kidneys	0.18	0.22	0.30	0.43	0.76
Liver	0.0095	0.012	0.018	0.025	0.041
Lungs	0.0025	0.0035	0.0052	0.0080	0.015
Muscles	0.0029	0.0036	0.0052	0.0077	0.014
Oesophagus	0.0017	0.0023	0.0034	0.0054	0.0094
Ovaries	0.0035	0.0047	0.0070	0.011	0.019
Pancreas	0.0090	0.011	0.016	0.023	0.037
Red marrow	0.0039	0.0047	0.0068	0.0090	0.014
Skin	0.0015	0.0018	0.0029	0.0045	0.0085
Spleen	0.013	0.017	0.026	0.038	0.061
Testes	0.0018	0.0024	0.0037	0.0053	0.010
Thymus	0.0017	0.0023	0.0034	0.0054	0.0094
Thyroid	0.0015	0.0019	0.0031	0.0052	0.0094
Urinary bladder wall	0.018	0.023	0.029	0.031	0.057
Uterus	0.0045	0.0056	0.0083	0.011	0.019
Remaining organs	0.0029	0.0037	0.0052	0.0077	0.014
<b>Effective dose (mSv/MBq)</b>	<b>0.0088</b>	<b>0.011</b>	<b>0.015</b>	<b>0.021</b>	<b>0.037</b>

The effective dose resulting from the administration of an activity of 120 MBq for an adult weighing 70 kg is about 1.06 mSv.

For an administered activity of 120 MBq the typical radiation dose to the target organ (kidney) is about 22 mGy and the typical radiation doses to the critical organs are: urinary bladder wall: 2.2 mGy, spleen: 1.6 mGy and adrenals: 1.4 mGy.

## 12. INSTRUCTIONS FOR PREPARATION OF RADIOPHARMACEUTICALS

Withdrawals should be performed under aseptic conditions. The vials must never be opened. After disinfecting the stopper, the solution should be withdrawn via the stopper using a single dose syringe fitted with suitable protective shielding and a disposable sterile needle or using an authorised automated application system.

If the integrity of this vial is compromised, the product should not be used.

## Method of preparation

Usual precautions regarding sterility and radioprotection should be respected.

Take a vial from the kit and put it in an appropriate lead shielding.

Using a hypodermic syringe, introduce through the rubber stopper 1 to 6 mL of sterile pyrogen-free sodium pertechnetate ( $^{99m}\text{Tc}$ ) injection corresponding to maximum 3.7 GBq. Sodium pertechnetate ( $^{99m}\text{Tc}$ ) injection should comply with European Pharmacopoeia specifications.

Do not use a breather needle as the contents are under nitrogen: after introduction of the volume of sodium pertechnetate ( $^{99m}\text{Tc}$ ) injection, without removing the needle, withdraw an equivalent volume of nitrogen in order to avoid excess pressure in the vial.

Shake for 5 to 10 minutes.

The obtained preparation is a clear and colourless solution, with a pH ranging between 2.3 and 3.5.

Before use, limpidity of the solution after preparation, pH, radioactivity and gamma spectrum will be checked.

The vial should never be opened and must be kept inside its lead shielding. The solution should be removed aseptically through the stopper with a sterile lead protected syringe.

### - Quality control

The quality of labelling (radiochemical purity) could be checked according to the following procedure.

## **Method**

Ascending paper chromatography

## **Materials and reagents**

1. Chromatographic paper  
Whatman 1 strip of sufficient length and not less than 2.5 cm wide.  
Trace two fine lines parallel to the ends of the strips, the one being called "deposit line" at 2.5 cm, the other one being called "solvent line" at 10 cm from the "deposit line".
2. Mobile phase  
methyl ethyl ketone
3. Glass tank  
Glass tank of suitable size for the chromatographic paper used, ground at the top to take a closely fitting lid. In the top of the tank is a device which suspends the chromatographic paper and is capable of being lowered without opening the chamber.
4. Miscellaneous  
Forceps, scissors, syringes, needles, appropriate counting assembly.

## Procedure

1. Place into the glass tank a layer of 2 cm deep of the mobile phase.
2. Apply a spot of the preparation to the "deposit line" of the paper strip using a syringe and needle and dry in air.
3. Using forceps, insert the paper strip into the tank and close the lid. Lower the paper into the mobile phase and allow the solvent to migrate to the "solvent line".
4. Remove the paper strip with forceps and dry in air.
5. Determine distribution of radioactivity with an appropriate detector. Identify each radioactive spot by calculating the Rf. The Rf of technetium ( $^{99m}\text{Tc}$ ) succimer is 0, and that of pertechnetate ion (free ( $^{99m}\text{Tc}$ ) technetium) is 1. Measure the radioactivity of each spot by integration of the peaks.

### 6. Calculations

Calculate the percentage of technetium ( $^{99m}\text{Tc}$ ) succimer (radiochemical purity)

$$\% \text{ technetium } (^{99m}\text{Tc}) \text{ succimer} = \frac{\text{Radioactivity of the spot at Rf 0}}{\text{Total radioactivity of the paper strip}} \times 100$$

Calculate the percentage of free ( $^{99m}\text{Tc}$ ) technetium

$$\% \text{ free } (^{99m}\text{Tc}) \text{ technetium} = \frac{\text{Radioactivity of the spot at Rf 1}}{\text{Total radioactivity of the paper strip}} \times 100$$

7. The percentage of technetium ( $^{99m}\text{Tc}$ ) succimer (radiochemical purity) should be at least 95 % and the percentage of free ( $^{99m}\text{Tc}$ ) technetium should not be greater than 2 %.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.